ROIVANT SCIENCES LTD. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
ROIVANT SCIENCES LTD. (ROIV) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $568.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-06
- ROIVANT SCIENCES LTD. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $568.19M.
- ROIVANT SCIENCES LTD. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-06-30 was $0.00.
- ROIVANT SCIENCES LTD. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2026 was $1.12B.
- ROIVANT SCIENCES LTD. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $0.00.
- ROIVANT SCIENCES LTD. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $0.00.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|
| 2026-06-30 | $568.19M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.12B 10-K · filed 2026-05-20 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $0.00 10-K · filed 2026-05-20 | |
| 2024-03-31 | $0.00 10-K · filed 2026-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |